(NYSE: NUVB) Nuvation Bio's forecast annual revenue growth rate of 89.41% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.39%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.61%.
Nuvation Bio's revenue in 2026 is $62,902,000.On average, 13 Wall Street analysts forecast NUVB's revenue for 2026 to be $66,429,317,901, with the lowest NUVB revenue forecast at $48,625,384,758, and the highest NUVB revenue forecast at $81,209,154,629. On average, 12 Wall Street analysts forecast NUVB's revenue for 2027 to be $105,075,184,492, with the lowest NUVB revenue forecast at $74,500,526,951, and the highest NUVB revenue forecast at $142,938,957,183.
In 2028, NUVB is forecast to generate $149,769,243,911 in revenue, with the lowest revenue forecast at $101,442,792,822 and the highest revenue forecast at $266,746,159,579.